

Curriculum Vitae

Name	Sang Joon Shin	
Current Position & Affiliation	Professor, Department of Internal Medicine, Yonsei University College of Medicine	
Country	Rep. of Korea	
Educational Background		

1992-1998 Yeungnam University College of Medicine, Daegu, Korea
 1998-1999 Rotating Internship, Asan Medical Center, Seoul, Korea
 2002-2006 Internal Medicine residency, Yeungnam University College of Medicine, Daegu, Korea
 2006-2008 Medical Oncology clinical fellow, Yonsei University College of Medicine, Seoul, Korea

Professional Experience

2009-2013 Assistant Professor, Medical Oncology, Severance Hospital, Yonsei Cancer Center
 2012-2014 Visiting Assistant Professor, MD Anderson Cancer Center, Texas, USA
 2013-2018 Associate Professor, Medical Oncology, Severance Hospital, Yonsei Cancer Center
 2018-present Professor, Medical Oncology, Severance Hospital, Yonsei Cancer Center

Professional Organizations

2006-present Korean Association of Internal Medicine
 2006-present Korean Cancer Association
 2006-present Korean Society of Medical Oncology

Main Scientific Publications

1. Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators.

- Byun HK, Chang JS, Jung M, Koom WS, Chung KY, Oh BH, Roh MR, Kim KH, Lee CK, Shin SJ. *Front Oncol.* 2021 May 27;11:659754
2. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. *Nature.* 2021 Jun;594(7863):418-423.
 3. Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma. Park CK, Heo J, Ham WS, Choi YD, Shin SJ, Cho NH. *Cancer Res Treat.* 2021 Mar 17
 4. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. *J Clin Oncol.* 2021 Mar 20;39(9):1029-1039.
 5. Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies. Zhang W, Mathisen M, Goodman GR, Forbes H, Song Y, Bertran E, Demidov L, Shin SJ. *Clin Pharmacol Drug Dev.* 2021 Jan;10(1):39-45
 6. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, Kim TS, Choi SJ, Kim HD, Han JW, Kwon M, Kim JH, Lee AJ, Nam SK, Bae SJ, Lee SB, Shin SJ, Park SH, Ahn JB, Jung I, Lee KY, Park SH, Kim H, Min BS, Shin EC. *Sci Immunol.* 2019 Nov 8;4(41)
-